Dalton Supporting Canadian Pharmaceutical Innovation
Toronto, Ontario, Canada – January 22, 2026
Dalton Pharma Services is excited to collaborate with Vimy Pharmaceuticals, a Toronto-based company who has researched and developed a made-in-Canada generic version of Semaglutide to the Canadian Market.
As highlighted in the interview with BNN Bloomberg, this initiative represents a major step forward in strengthening Canada’s pharmaceutical manufacturing capabilities with a focus on quality, accessibility, and domestic innovation.
Dalton Pharma Services supports Canadian and global pharmaceutical companies by providing regulatory-focused formulation development and cGMP manufacturing.
We are proud that Dalton’s expertise in formulation development and manufacturing is helping accelerate this important milestone for Canadian patients and the healthcare system.
Watch the full interview here as Farris Smith, founder & president of Vimy Pharmaceuticals, joins BNN Bloomberg to discuss 2026 outlook on the weight loss drugs space.